Advanced Cell Technology Seeking International Partners for its Therapeutic Programs
News Dec 10, 2007
Advanced Cell Technology, Inc. has announced that it is seeking international partners for each of its three lead therapeutic programs, including its Myoblast program for treating heart failure, its Retinal Pigment Epithelium program for treating degenerative retinal disease, and the Hemangioblast program for the treatment of blood and cardiovascular indications. The company is making significant progress in the development of each of these therapeutic programs within the United States.
Advanced Cell Technology has made a strategic decision to seek partners for each of these programs internationally, including regions such as Europe, the Middle East and Asia, as the company recognizes that there is strong interest in the field of stem cells worldwide.
ACT has asked Burrill & Company, which it hired last year to advise on a number of strategic initiatives, to renew its focus on seeking international partners. Interested parties worldwide should contact Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology.
“We recognize that there is material interest in the stem cell and regenerative medicine field globally and will seek strong partners from the worldwide medical community to pursue our programs outside of the United States and complement the work we are doing at home. We are very pleased to continue our successful relationship with Burrill & Company and utilize their extensive global network to further these discussions,” said Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.